Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC
Language English Country Greece Media print
Document type Journal Article
PubMed
29061834
DOI
10.21873/anticanres.12102
PII: 37/11/6469
Knihovny.cz E-resources
- Keywords
- Erlotinib, NSCLC, diarrhoea, lung cancer, serum concentration, skin rash, survival, toxicity,
- MeSH
- Survival Analysis MeSH
- ErbB Receptors genetics MeSH
- Erlotinib Hydrochloride adverse effects blood therapeutic use MeSH
- Exanthema chemically induced MeSH
- Humans MeSH
- Lung Neoplasms blood drug therapy genetics MeSH
- Carcinoma, Non-Small-Cell Lung blood drug therapy genetics MeSH
- Disease-Free Survival MeSH
- Antineoplastic Agents adverse effects blood therapeutic use MeSH
- Diarrhea chemically induced MeSH
- Retrospective Studies MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- EGFR protein, human MeSH Browser
- ErbB Receptors MeSH
- Erlotinib Hydrochloride MeSH
- Antineoplastic Agents MeSH
BACKGROUND: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment. RESULTS: There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353). CONCLUSION: Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinib toxicity.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Department of Analytical Chemistry Faculty of Sciences Charles University Prague Czech Republic
References provided by Crossref.org
